Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-06

Clinical Trial Update: Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of midostaurin in patients with aggressive systemic mastocytosis or mast cell leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Midostaurin (midostaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-06-06